"investigational"@en . . "approved"@en . . "* renal cl=11.6+/- 3.9 L/hr [Healthy subjects receiving repeat doses of 320 mg orally]"@en . . . . . . . . . . . . "* 1.66 to 12.12 L/kg"@en . "The bactericidal action of gemifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination."@en . . "175463-14-6"@en . "Gemifloxacin is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth."@en . "Gemifloxacin mesilate"@en . . . . "gemifloxacin mesylate"@en . . . "For the treatment of bacterial infection caused by susceptible strains such as S. pneumoniae, H. influenzae, H. parainfluenzae, or M. catarrhalis, S. pneumoniae (including multi-drug resistant strains [MDRSP]), M. pneumoniae, C. pneumoniae, or K. pneumoniae."@en . . . . . . . . . " "@en . . . "Enteric bacteria and other eubacteria"@en . . . "Rapidly absorbed from the gastrointestinal tract. The absolute bioavailability averages approximately 71%."@en . "Take without regard to meals."@en . . . . . . . . . "Gemifloxacin and its metabolites are excreted via dual routes of excretion.Following oral administration of gemifloxacin to healthy subjects, a mean (\u00B1 SD) of 61 \u00B1 9.5% of the dose was excreted in the feces and 36 \u00B1 9.3% in the urine as unchanged drug and metabolites. The mean (\u00B1 SD) renal clearance following repeat doses of 320 mg was approximately 11.6 \u00B1 3.9 L/hr (range 4.6-6 L/hr), which indicates active secretion is involved in the renal excretion of gemifloxacin."@en . . . "\"DrugSyn.org\":http://www.drugsyn.org/Gemifloxacin.htm"@en . "7 (± 2) hours"@en . . . . . "Factiv"@en . . "60-70%"@en . . . . "Gemifloxacin"@en . . .